Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Receivables (2016 - 2025)

Historic Change in Receivables for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $368000.0.

  • NovaBay Pharmaceuticals' Change in Receivables changed N/A to $368000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $320000.0, marking a year-over-year increase of 28181.82%. This contributed to the annual value of -$291000.0 for FY2024, which is 6560.28% up from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Change in Receivables of $368000.0 as of Q3 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Change in Receivables registered a high of $1.0 million during Q3 2022, and its lowest value of -$1.4 million during Q3 2023.
  • For the 5-year period, NovaBay Pharmaceuticals' Change in Receivables averaged around -$61066.7, with its median value being -$68000.0 (2021).
  • Over the last 5 years, NovaBay Pharmaceuticals' Change in Receivables had its largest YoY gain of 102941.18% in 2022, and its largest YoY loss of 71958.76% in 2022.
  • NovaBay Pharmaceuticals' Change in Receivables (Quarter) stood at -$189000.0 in 2021, then increased by 15.34% to -$160000.0 in 2022, then surged by 141.88% to $67000.0 in 2023, then tumbled by 171.64% to -$48000.0 in 2024, then surged by 866.67% to $368000.0 in 2025.
  • Its Change in Receivables stands at $368000.0 for Q3 2025, versus -$48000.0 for Q4 2024 and -$243000.0 for Q1 2024.